# Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)

> **NCT04165486** · PHASE1 · RECRUITING · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Multiple System Atrophy

## Interventions

- **DRUG:** ION464
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04165486
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-21
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04165486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04165486, "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04165486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*